Share on LinkedInShare on LinkedIn

ARTICLE · 20 MAY 2014

Pharma In Brief - Court Imposes Cost Sanctions For Repeat Litigation Under NOC Regulations

The Federal Court dismissed Bayer’s application for an Order prohibiting a Notice of Compliance to Apotex Inc. for its generic YAZ® birth control product.

CanadaIntellectual Property

Case: Bayer Inc. and Bayer Pharma Aktiengesellschaft v. Apotex Inc. et al. ("Bayer")

Drug: drospirenone + ethinylestradiol (YAZ®)

Nature of case: Prohibition proceeding under Patented Medicines (Notice of Compliance) Regulations ("Regulations")

Date of decision: May 1, 2014

Summary

On May 1, 2014, the Federal Court dismissed Bayer's application for an Order prohibiting the Minister of Health from issuing a Notice of Compliance to Apotex Inc. ("Apotex") for its generic YAZ® birth control product until the expiry of Canadian Patent No. 2,179,728 ("Apotex Proceeding"). This decision reaffirms the Court's approach to avoid repeat s. 6 litigation on the same patent by brand manufacturers against multiple generics under the Regulations.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from